- Home
- SNCY vs DSGN Comparison
SNCY vs DSGN Comparison
Compare SNCY & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNCY | DSGN |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.0M | 819.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNCY | DSGN |
|---|---|---|
| Price | $16.17 | $14.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $19.50 | $15.25 |
| AVG Volume (30 Days) | ★ 627.1K | 553.4K |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,126,769,000.00 | N/A |
| Revenue This Year | $12.27 | N/A |
| Revenue Next Year | $7.51 | N/A |
| P/E Ratio | $37.60 | ★ N/A |
| Revenue Growth | ★ 4.74 | N/A |
| 52 Week Low | $10.14 | $3.31 |
| 52 Week High | $22.29 | $17.25 |
Technical Indicators
Market Signals| Indicator | SNCY | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 53.55 |
| Support Level | $15.36 | $9.25 |
| Resistance Level | $17.93 | $17.25 |
| Average True Range (ATR) | 0.65 | 1.23 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 49.16 | 30.36 |
Price Performance
Historical ComparisonAbout SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.